BIOND BIOLOGICS: FROM INNOVATIVE SCIENCE TO THE CLINIC; TRANSFORMING THE TREATMENT OF CANCER

Tehila Ben-Moshe\textsuperscript{1}, Itay Friedman\textsuperscript{2}, Ilana Mandel\textsuperscript{3}, \textsuperscript{1} CEO, Biond Biologics, \textsuperscript{2} VP Clinical Development, Biond Biologics, \textsuperscript{3} VP Discovery, Biond Biologics

- **Investment Rational**
  Biond Biologics is a science-driven company, engaged in the discovery of targets with the potential to transform patient care. We develop innovative medicines for novel targets by unraveling immunoregulatory pathways and by enabling antibody-targeting of intra-cellular proteins. Biond was founded by an experienced team who led cCam Biotherapeutics, a clinical stage, immuno-oncology company acquired by Merck.

- **Business Strategy**
  Biond focuses on cancer and autoimmune targets. Targets are discovered internally, and we advance our in-house developed biotherapeutics to clinical studies. Biond aims to partner with global pharma companies prior to commercialization. Longer term, Biond expects its biologics’ cell internalization platform to generate a growing pipeline of highly sought-after intracellular targets, which will be further developed internally or through collaborations.

- **Core Technology**
  Biond’s lead asset is BND-22, a novel macrophage activator that targets an inhibitory immune receptor. BND-22 generates an anti-tumor response by blocking the targeted receptor which binds to a yet untargeted, however well-established immune evasion tumor antigen. BND-22 is currently in IND enabling studies and is planned to enter the clinic in Q1 2021.

- **Product Profile/Pipeline**
  Besides BND-22, Biond’s research team has uncovered a novel immune suppression mechanism presenting opportunities for developing drugs enhancing anti-tumor activity. In parallel, the company is advancing a cell internalization platform which is expected to dramatically expand the universe of potential drug targets. It is designed to enable internalization of proteins into cells with the goal of targeting critical intracellular targets.

- **What’s Next?**
  Biond’s lead asset, BND-22, has entered manufacturing and an IND is planned to be submitted in H2 2020. Proof-of-concept studies of our biologics’ cell internalization platform have been completed, and the technology will be studied next in models of specific intracellular cancer targets.